You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Ventilation Stethoscope using Hyperpolarized Xenon

    SBC: MIRTECH INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Ventilator Induced Lung Injury (VILI) is a common cause of morbidity and sometimes mortality in critically ill patients with respiratory failure. The types of VILI include barotraumas, volutrauma, atelectrauma, and biotrauma. Thus ventilator setting is a delicate balance between achieving sufficient ventilation but avoiding excessive pressure and overdistensio ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Non-invasive neonatal respiration monitor

    SBC: FLUOROMETRIX CORPORATION            Topic: NICHD

    DESCRIPTION (provided by applicant): Preterm birth requires technologies for supporting immature organ systems on one hand while minimizing technology-induced injury on the other that may contribute to long-term adverse outcomes. Specific problems of thiskind are extremes in arterial partial pressure of oxygen and carbon dioxide. A variety of pathological conditions are known to result from both ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Next Generation Therapeutics for Hemoglobinopathies

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthcare system gt 1 billion annually. Patients have chronic disabling morbidity and early mortality. Fetal hemoglobin (HbF: a2,g2) is another endogenous type of hemoglobin normally present in all humans, ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Using combinatorial control to improve transgene expression specificity in plants

    SBC: GRASSROOTS BIOTECHNOLOGY, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): It is currently estimated that 15% of the world's population is undernourished and 5 million childhood deaths a year are attributable to malnutrition. The ability to feed the world in the future will be even more difficult due to population growth, climate change, water scarcity, and competition for land. It is widely recognized that advances in agricultu ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government